BiotechTube
Home/Pipeline/NK‑Thera

NK‑Thera

Hematologic Malignancies

Phase 1/2Active

Key Facts

Indication
Hematologic Malignancies
Phase
Phase 1/2
Status
Active
Company
Vectorite Biomedical

About Vectorite Biomedical

Taiwan biotech delivering DC‑ and NK‑cell immunotherapies and exosome products for oncology and regenerative medicine.

View full company profile

Therapeutic Areas

OncologyImmunologyRegenerative Medicine

Other Hematologic Malignancies Drugs

DrugCompanyPhase
CER-T Cell PlatformCERo TherapeuticsPre-clinical
Not Specified (Hematologic Malignancies)AbelZeta PharmaClinical
PredicineHEME™PredicineCommercial
Orca-TBristol Myers SquibbPhase 3
Trichostatin A (TSA)Vanda PharmaceuticalsDevelopment
DARIC-NK ProgramCoeptis TherapeuticsPreclinical
TSC-102-A01TScan TherapeuticsPreclinical
TSC-102-A03TScan TherapeuticsPreclinical
LBL-007LakeShore BiopharmaPhase 1/2